---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-073321"
form_type: "8-K"
ticker: "IXHL"
cik: "0001873875"
company_name: "Incannex Healthcare Inc."
filed_at: "2025-08-08T23:59:59+00:00"
generated_at: "2026-05-17T16:48:12.220791+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Incannex reports positive Phase 2 data for IHL-42X in obstructive sleep apnoea; AHI reductions up to 83%

## Summary
- Low- and high-dose IHL-42X achieved statistically significant reduction in AHI vs placebo (p<0.05); max AHI reduction 83% in high-dose group.
- 41.2% of high-dose group achieved >30% AHI reduction; 14.7% had >50% reduction; no reduction in REM sleep.
- 89.5% of patients reporting improvement described change as meaningful; benefits included improved sleep quality and reduced daytime fatigue.
- No serious adverse events; treatment-emergent adverse effects infrequent, mild/moderate; drug well tolerated.
- CEO notes share price volatility, states company is well-capitalized and considering strategic levers including anti-dilution measures.

## SEC filing metadata
- accession: 0001213900-25-073321
- form_type: 8-K
- ticker: IXHL
- cik: 0001873875
- company_name: Incannex Healthcare Inc.
- filed_at: 2025-08-08T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1873875/000121390025073321/0001213900-25-073321-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1873875/000121390025073321/ea0252400-8k_incannex.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-073321
- JSON: https://secwatch.observer/filing/0001213900-25-073321.json
- Plain text: https://secwatch.observer/filing/0001213900-25-073321.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.